Subscribe To

Price Alert Latest News Economic Calendar News

VVOS / Vivos Therapeutics says 2022 and early 2023 accomplishments sets stage for potential revenue growth this year

Vivos Therapeutics (NASDAQ:VVOS), Inc has announced its fiscal 2022 financial results and provided an operational update, saying it believes its 2022 and early 2023 accomplishments, including the completion of a capital raise for net proceeds of about $7.4 million, cost reductions and a new technology acquisition, have set the stage for potential 2023 revenue growth. The medical device and technology company recorded revenue of $16 million for the full year ended December 31, 2022, which excludes about $2.5 million of Vivos Integrated Provider (VIP) enrollment revenue that is expected to be recognized during the next 17 months. Read More

Demo Live Account See Partner Details

Content Topics

Vivos

Therapeutics

Says

2022

Early

2023

Accomplishments

Sets

Potential

Revenue

Growth

Stock

VVOS

Posted: Mar 30 2023, 16:49

Author Name: Proactive Investors

VVOS News

By Proactive Investors
October 26, 2023

Vivos Therapeutics reveals 1-for-25 reverse stock split

Vivos Therapeutics (NASDAQ:VVOS) has announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common shares effec

By Proactive Investors
October 24, 2023

Vivos Therapeutics inks distribution agreement for its oral devices with Lincare

Vivos Therapeutics (NASDAQ:VVOS) announced it has signed a United States-wide distribution agreement for its oral appliances with Lincare, a leading

By Proactive Investors
October 20, 2023

Vivos Therapeutics can help you get a better sleep (really)

Better sleep is better health, period. But for many people, it's not that easy.

By Zacks Investment Research
October 12, 2023

Here Is Why Bargain Hunters Would Love Fast-paced Mover Vivos Therapeutics, Inc. (VVOS)

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Vivos Therapeutics, Inc. (VVOS) co

By Proactive Investors
October 11, 2023

Vivos Therapeutics to kick off clinical trial at Stanford Medicine

Vivos Therapeutics (NASDAQ:VVOS) Inc has announced that its flagship daytime-nighttime appliance (DNA) will be tested in a clinical trial at Stanford

By Proactive Investors
October 5, 2023

Vivos Therapeutics shares gains continue on Noum collaboration

Vivos Therapeutics (NASDAQ:VVOS) shares continued to make gains on Thursday morning after the developer of oral appilances for the treatment of sleep

By Proactive Investors
October 4, 2023

Vivos Therapeutics announces strategic agreements with Ormco and On Demand Orthodontist

Vivos Therapeutics (NASDAQ:VVOS) has announced two strategic agreements that will expand its current product line of oral appliances for the treatment

By Proactive Investors
October 2, 2023

Vivos Therapeutics previews upcoming conference featuring headline speaker James Nestor

Vivos Therapeutics (NASDAQ:VVOS) said it will welcome best-selling author James Nestor to headline its Fifth Annual Breathing Wellness Conference. Nes

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.